Table 5.
Women | p | Men | p | |||
---|---|---|---|---|---|---|
NTX N=29 | PLC N=28 | NTX N=78 | PLC N=76 | |||
Nausea | 38% | 8% | 0.01 | 13% | 10% | 0.82 |
Falling Asleep | 24% | 46% | 0.09 | 23% | 24% | 0.77 |
Staying asleep | 17% | 54% | 0.00 | 36% | 31% | 0.79 |
Decreased Appetite | 17% | 12% | 0.56 | 25% | 12% | 0.09 |
Headache | 48% | 41% | 0.47 | 34% | 19% | 0.08 |
Dizzy | 7% | 8% | 0.91 | 13% | 3% | 0.09 |
Fatigue | 52% | 41% | 0.33 | 31% | 30% | 0.93 |
Sexual Dysfunction | 21% | 35% | 0.26 | 32% | 35% | 0.63 |
p is comparing NTX (naltrexone) to PLC (placebo).